Sign in
WithdrawnNo phase

Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

Key facts

Who runs it
Northwestern University
Where
Bethesda, United StatesSee the site
Trial code
Status
Withdrawn
Started
Aug 2025
Expected to end
May 2028
Type of study
Observational
Record updated
28 August 2026
Why it stopped
Due to funding issues the study did not move forward with prospective enrollment

Who can take part

Age
18 years to 89 years
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Elevated PSA (4.0-10.0 ng/ml) or abnormal digital rectal exam with PSA of 2.00-10.00 ng/ml as indicated in the patient's lab report
  • Patients must be biopsy naïve, confirmed with patient or medical record
  • Patients must be male, ≥18 and ≤ 89 years of age
  • Patient must have a life expectancy ≥10 years, determined by PI
  • Patients must exhibit an ECOG performance status of 0-2, as noted in their medical record

Who cannot take part

  • Patients who are on a 5-α-reductase inhibitor within 12 months of enrollment, as confirmed by medical record
  • Patients who are receiving or who received prostate cancer treatment (e.g., androgen deprivation therapy, surgery, radiation therapy or adjuvant/neoadjuvant therapy with investigational drugs) per their medical record
  • Patients who have had a prostate infection within 1 month of enrollment, as confirmed by medical record
  • Vulnerable populations: Prisoners or adult men >89 years old
  • Patients who've had an invasive urological procedure within 1 month of enrollment, as confirmed by their medical record and patient reporting
  • Patients with no access to the rectum for a transrectal ultrasound, as determined by the Urologist
  • Patients with a contraindication to magnetic resonance imaging (MRI)

Where in United States

  • National Institutes of HealthBethesda, United States

About the trial

What the trial wants to find out

The purpose of this study is to develop a new way to diagnose prostate cancer through the use of artificial intelligence. The goal is for this new method to reduce delays in diagnoses and to avoid invasive procedures such as biopsies.

The group in the trial

  • Cohort 1

    Biopsy naïve participants with elevated PSA (4.0-10.0 ng/ml) or abnormal digital rectal exam with PSA of 2.00-10.00 ng/ml as indicated in their lab report.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
28 August 2026